News

ERC and ERT urge for full EU budget
Enlarge image

FundingEU

ERC and ERT urge for full EU budget

04.02.2013 - European company and research leaders have urged EU heads to greenlight €80bn for Horizon2020.

The joint letter of the European Round Table of Industrialists (ERT) and European Research Council (ERC) arrived some days before the EU Council will decide over the proposed €80m R&D budget of the EU innovation programme from 2014-2020. „We call on Europe’s leaders to approve the €80bn funding programme for research and innovation, Horizon 2020. This will lay the foundations for growth in Europe“, said ERC chief Helga Nowotny and ERT head Leif Johansson. The stakeholders warned that „any reduction in the funding to support excellent research will result in Europe having limited means to attract outstanding talent in a highly competitive global market.“ 

The EU heads will meet this week after negotiations of the EU Summit last November failed. A week before Council President Hermann van Rompuy’s initial budget proposal was withdrawn, 44 Nobel laureates had already warned in about the consequences of budget cuts to research and innovation. Over 100,000 Internet users supported their call not to slash the European Research Council (ERC) budget for excellent fundamental research. However, initial ideas discussed by the heads of EU Member States at the end of November foresaw cutting the €80bn innovation programme’s proposed budget by 12% (about €10bn) or more in favour of agriculture and structural funds.

This time, the research lobbyists try to make a stronger case: “Industry has long realised that one of its most precious assets is people“, stressed Nowotny and Johansson. „A continued supply of well-trained scientists and entrepreneurs is essential, especially for SMEs and start-up companies. Europe’s future can only be built on its brains.“

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/erc-and-ert-urge-for-full-rd-budget.html

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

BiofuelFinlandSwedenUK

10.06.2015 St1 Biofuels has expanded beyond the Finnish borders and opened a bioethanol plant in Sweden. The plant will convert leftovers and waste from bakeries to biofuel.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.07 CHF16.67%
  • EUROFINS SCIENTIFIC (F)283.68 EUR11.25%
  • MEDIGENE (D)9.35 EUR10.65%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.00%
  • NORDIC NANOVECTOR (N)24.40 NOK-9.29%
  • EVOTEC (D)3.33 EUR-6.20%

TOP

  • DBV Technologies (F)55.76 EUR31.0%
  • VERONA PHARMA (UK)5.20 GBP24.7%
  • MEDIGENE (D)9.35 EUR20.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NORDIC NANOVECTOR (N)24.40 NOK-30.5%
  • TRANSGENE (F)3.75 EUR-24.2%

TOP

  • ADOCIA (F)69.25 EUR398.9%
  • 4SC (D)4.88 EUR369.2%
  • WILEX (D)3.54 EUR321.4%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.20 SEK-68.1%
  • NEOVACS (F)1.13 EUR-66.9%

No liability assumed, Date: 01.07.2015